FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3026349259> ?p ?o ?g. }

• W3026349259 endingPage "267" @default.
• W3026349259 startingPage "267" @default.
• W3026349259 abstract "This study investigates GT-1 (also known as LCB10-0200), a novel-siderophore cephalosporin, inhibited multidrug-resistant (MDR) Gram-negative pathogen, via a Trojan horse strategy exploiting iron-uptake systems. We investigated GT-1 activity and the role of siderophore uptake systems, and the combination of GT-1 and a non-β-lactam β-lactamase inhibitor (BLI) of diazabicyclooctane, GT-055, (also referred to as LCB18-055) against molecularly characterised resistant Escherichia coli, Klebsiella pneumoniae and Acinetobacter spp. isolates. GT-1 and GT-1/GT-055 were tested in vitro against comparators among three different characterised panel strain sets. Bacterial resistome and siderophore uptake systems were characterised to elucidate the genetic basis for GT-1 minimum inhibitory concentrations (MICs). GT-1 exhibited in vitro activity (≤2 μg/mL MICs) against many MDR isolates, including extended-spectrum β-lactamase (ESBL)- and carbapenemase-producing E. coli and K. pneumoniae and oxacillinase (OXA)-producing Acinetobacter spp. GT-1 also inhibited strains with mutated siderophore transporters and porins. Although BLI GT-055 exhibited intrinsic activity (MIC 2–8 μg/mL) against most E. coli and K. pneumoniae isolates, GT-055 enhanced the activity of GT-1 against many GT-1–resistant strains. Compared with CAZ-AVI, GT-1/GT-055 exhibited lower MICs against E. coli and K. pneumoniae isolates. GT-1 demonstrated potent in vitro activity against clinical panel strains of E. coli, K. pneumoniae and Acinetobacter spp. GT-055 enhanced the in vitro activity of GT-1 against many GT-1–resistant strains." @default.
• W3026349259 created "2020-05-29" @default.
• W3026349259 creator A5001961835 @default.
• W3026349259 creator A5013212800 @default.
• W3026349259 creator A5013493851 @default.
• W3026349259 creator A5032474262 @default.
• W3026349259 creator A5042742269 @default.
• W3026349259 creator A5052639020 @default.
• W3026349259 creator A5059060036 @default.
• W3026349259 creator A5079033596 @default.
• W3026349259 date "2020-05-20" @default.
• W3026349259 modified "2023-09-24" @default.
• W3026349259 title "In Vitro Activity of a Novel Siderophore-Cephalosporin, GT-1 and Serine-Type β-Lactamase Inhibitor, GT-055, against Escherichia coli, Klebsiella pneumoniae and Acinetobacter spp. Panel Strains" @default.
• W3026349259 cites W1513515886 @default.
• W3026349259 cites W1548038775 @default.
• W3026349259 cites W1776609194 @default.
• W3026349259 cites W1856107967 @default.
• W3026349259 cites W2004548026 @default.
• W3026349259 cites W2014723793 @default.
• W3026349259 cites W2044894353 @default.
• W3026349259 cites W2074084995 @default.
• W3026349259 cites W2080095202 @default.
• W3026349259 cites W2081256428 @default.
• W3026349259 cites W2089643339 @default.
• W3026349259 cites W2095617611 @default.
• W3026349259 cites W2096160505 @default.
• W3026349259 cites W2102874012 @default.
• W3026349259 cites W2112160620 @default.
• W3026349259 cites W2120902911 @default.
• W3026349259 cites W2124662574 @default.
• W3026349259 cites W2126984210 @default.
• W3026349259 cites W2128912763 @default.
• W3026349259 cites W2134852597 @default.
• W3026349259 cites W2135113667 @default.
• W3026349259 cites W2141484353 @default.
• W3026349259 cites W2142343447 @default.
• W3026349259 cites W2143325926 @default.
• W3026349259 cites W2152359855 @default.
• W3026349259 cites W2160853241 @default.
• W3026349259 cites W2163025725 @default.
• W3026349259 cites W2331140546 @default.
• W3026349259 cites W2578335596 @default.
• W3026349259 cites W2581571791 @default.
• W3026349259 cites W2609935804 @default.
• W3026349259 cites W2733797945 @default.
• W3026349259 cites W2749240848 @default.
• W3026349259 cites W2779019546 @default.
• W3026349259 cites W2789500779 @default.
• W3026349259 cites W2886433327 @default.
• W3026349259 cites W2897856090 @default.
• W3026349259 cites W2911839824 @default.
• W3026349259 cites W2923658736 @default.
• W3026349259 cites W2925800094 @default.
• W3026349259 cites W2946322901 @default.
• W3026349259 cites W2982549624 @default.
• W3026349259 doi "https://doi.org/10.3390/antibiotics9050267" @default.
• W3026349259 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7277296" @default.
• W3026349259 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32443875" @default.
• W3026349259 hasPublicationYear "2020" @default.
• W3026349259 type Work @default.
• W3026349259 sameAs 3026349259 @default.
• W3026349259 citedByCount "16" @default.
• W3026349259 countsByYear W30263492592020 @default.
• W3026349259 countsByYear W30263492592021 @default.
• W3026349259 countsByYear W30263492592022 @default.
• W3026349259 countsByYear W30263492592023 @default.
• W3026349259 crossrefType "journal-article" @default.
• W3026349259 hasAuthorship W3026349259A5001961835 @default.
• W3026349259 hasAuthorship W3026349259A5013212800 @default.
• W3026349259 hasAuthorship W3026349259A5013493851 @default.
• W3026349259 hasAuthorship W3026349259A5032474262 @default.
• W3026349259 hasAuthorship W3026349259A5042742269 @default.
• W3026349259 hasAuthorship W3026349259A5052639020 @default.
• W3026349259 hasAuthorship W3026349259A5059060036 @default.
• W3026349259 hasAuthorship W3026349259A5079033596 @default.
• W3026349259 hasBestOaLocation W30263492591 @default.
• W3026349259 hasConcept C104317684 @default.
• W3026349259 hasConcept C108319773 @default.
• W3026349259 hasConcept C2776315533 @default.
• W3026349259 hasConcept C2777058267 @default.
• W3026349259 hasConcept C2777637488 @default.
• W3026349259 hasConcept C2778523567 @default.
• W3026349259 hasConcept C501593827 @default.
• W3026349259 hasConcept C523546767 @default.
• W3026349259 hasConcept C54355233 @default.
• W3026349259 hasConcept C547475151 @default.
• W3026349259 hasConcept C55493867 @default.
• W3026349259 hasConcept C64778159 @default.
• W3026349259 hasConcept C86803240 @default.
• W3026349259 hasConcept C89423630 @default.
• W3026349259 hasConceptScore W3026349259C104317684 @default.
• W3026349259 hasConceptScore W3026349259C108319773 @default.
• W3026349259 hasConceptScore W3026349259C2776315533 @default.
• W3026349259 hasConceptScore W3026349259C2777058267 @default.
• W3026349259 hasConceptScore W3026349259C2777637488 @default.
• W3026349259 hasConceptScore W3026349259C2778523567 @default.
• W3026349259 hasConceptScore W3026349259C501593827 @default.
• W3026349259 hasConceptScore W3026349259C523546767 @default.

• next